CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The HIV antiretroviral drug Viramune can cause sometimes deadly liver damage but remains a key option for many patients, U.S. health officials warned on Wednesday. The Food and Drug Administration said doctors should weigh benefits and risks before prescribing the nonnucleoside reverse transcriptase inhibitor, manufactured by Boehringer Ingelheim. No serious liver toxicity or deaths have been reported when a single dose was given to prevent mother-to-child transmission of the deadly HIV virus that causes AIDS, the FDA said. Viramune, also known by its generic name nevirapine, is distributed for that use in African countries as part of President George Bush's effort to fight the spread of AIDS. The name-brand drug is also used in the United States. Controversy has swirled recently in Africa, with South Africa's ruling African National Congress accusing U.S. officials of conspiring with Boehringer Ingelheim, a private company based in Germany, to hide nevirapine's side effects. U.S. health officials dispute the charge. The FDA, in a statement, said cases of liver damage that produce a rash, fever, or other symptoms were more common with nevirapine than with other HIV-fighting drugs. Some instances have been fatal, including some in pregnant women. Females and patients with higher counts of infection-fighting CD4 immune system cells have greater risks of developing liver damage, the FDA said. The FDA said side-effect warnings had recently been revised on the drug's prescribing information. "In spite of the potential for serious and life-threatening liver toxicity and skin rashes with nevirapine, there are multiple reasons why nevirapine remains an important part of an HIV treatment regimen for many HIV-infected individuals worldwide," the FDA said in a statement. A spokeswoman for Boehringer Ingelheim said there would be no change in the company's policy of offering Viramune free of charge to developing countries for preventing mother-to-child transmissions of HIV. "There is no consequence for our donation or for supply of the drug for continuous treatment at reduced prices in developing countries," the spokeswoman said. "We do not expect any major effects on the behavior of doctors or on our sales as a result of the FDA warning." (Reuters)
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
21+ steamy photos of Scotland’s finest gay men in Elska Glasgow
February 01 2024 10:07 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Conjoined twins Lori Schappell and trans man George Schappell dead at 62
April 27 2024 6:13 PM
Latest Stories
Kamala Harris rides wave of Democratic energy at kickoff event in Wisconsin
July 23 2024 3:36 PM
'Devastated:' A six-week abortion ban will go into effect in Iowa next week
July 23 2024 2:28 PM
Four hours, 44,000 Black women, and one Zoom call
July 23 2024 2:17 PM
Record 1.2 million people show out for Cologne’s Pride parade
July 23 2024 10:51 AM
Here's how far-right activist Leonard Leo helped fund Bud Light boycott
July 23 2024 10:27 AM
Elon Musk’s comments about his trans daughter prove why she doesn’t speak to him
July 23 2024 9:16 AM
Nancy Pelosi endorses Kamala Harris for president
July 22 2024 4:07 PM
Charli XCX declares Kamala Harris IS brat & our next President's campaign agrees
July 22 2024 3:08 PM
Pete Buttigieg roasts JD Vance and his gay tech bro billionaire
July 22 2024 1:42 PM